title: Effect of dialysis modality on survival of hepatitis C-infected ESRF patients.
abstract: OBJECTIVE
  Hepatitis C virus (HCV) infection is associated with increased mortality and morbidity in end-stage renal failure (ESRF) patients. Despite a lower incidence and risk of transmission of HCV infection with peritoneal dialysis (PD), the optimal dialysis modality for HCV-infected ESRF patients is not known. The aim of this study was to evaluate the impact of dialysis modality on the survival of HCV-infected ESRF patients.
  
  
  METHODS
  The study included all adult incident ESRF patients in Australia and New Zealand who commenced dialysis between January 1, 1994, and December 31, 2008, and were HCV antibody-positive at the time of dialysis commencement. Time to all-cause mortality was compared between hemodialysis (HD) and PD according to modality assignment at day 90, using Cox proportional hazards model analysis.
  
  
  RESULTS
  A total of 424 HCV-infected ESRF patients commenced dialysis during the study period and survived for at least 90 days (PD n = 134; HD n = 290). Mortality rates were comparable between PD and HD in the first year (10.7 versus 13.8 deaths per 100 patient-years, respectively; adjusted hazard ratio [HR] 0.65, 95% CI 0.34 to 1.26) and thereafter (20 versus 15.9 deaths per 100 patient-years, respectively; HR 1.27, 95% CI 0.86 to 1.88).
  
  
  CONCLUSIONS
  The survival of HCV-infected ESRF patients is comparable between PD and HD.
authors: Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia.
authors: Bhadran
authors: B
authors: Bose
authors: Stephen P
authors: SP
authors: McDonald
authors: Carmel M
authors: CM
authors: Hawley
authors: Fiona G
authors: FG
authors: Brown
authors: Sunil V
authors: SV
authors: Badve
authors: Kathryn J
authors: KJ
authors: Wiggins
authors: Kym M
authors: KM
authors: Bannister
authors: Neil
authors: N
authors: Boudville
authors: Philip
authors: P
authors: Clayton
authors: David W
authors: DW
authors: Johnson
mesh_terms: D000328:Adult; D000368:Aged; D001315:Australia / Q000453:epidemiology; D015415:Biomarkers / Q000097:blood; D016009:Chi-Square Distribution; D006526:Hepatitis C / Q000175:diagnosis / Q000401:mortality*; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D007676:Kidney Failure, Chronic / Q000401:mortality* / Q000628:therapy*; D008875:Middle Aged; D009520:New Zealand; D010530:Peritoneal Dialysis / Q000401:mortality*; D016016:Proportional Hazards Models; D012042:Registries; D006435:Renal Dialysis / Q000401:mortality*; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D016019:Survival Analysis; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D018937:Hepatitis C Antibodies